Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
29.24
0.00 (0.00%)
Jun 18, 2026, 4:00 PM EDT - Market closed

COAG Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, COAG stock has a consensus rating of "Strong Buy" and an average price target of $41.75. The average 1-year stock price forecast is 42.78% higher than the current stock price, while the lowest is $36 (+23.12%) and the highest is $50 (+71.00%).

Price Target: $41.75 (+42.78%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$36$41.75$40.5$50
Change+23.12%+42.78%+38.51%+71.00%

Analyst Ratings

The average analyst rating for COAG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMay '26Jun '26
Strong Buy44
Buy00
Hold00
Sell00
Strong Sell00
Total44

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Jefferies
Jefferies
Buy
Maintains
$39
BuyMaintains$39+33.38%Jun 8, 2026
Evercore ISI
Evercore ISI
Buy
Initiates
$50
BuyInitiates$50+71.00%May 26, 2026
Wedbush
Wedbush
Buy
Initiates
$42
BuyInitiates$42+43.64%May 26, 2026
Goldman Sachs
Goldman Sachs
Buy
Initiates
$36
BuyInitiates$36+23.12%May 26, 2026

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.06
EPS Next Year
-2.45
from -3.06
Fiscal YearFY 2024FY 2025FY 2026
Period EndingDec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---
Operating Income
-50.38M-70.12M-106.26M
Net Income
-48.71M-63.91M-95.31M
EPS
---3.06
Free Cash Flow
--39.59M-86.00M
No. Analysts
--5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-2.48
Avg-3.06
Low-3.59

EPS Growth

EPS Growth20272028
High-
Avg-
Low-